ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

TNFRSF17

TNF receptor superfamily member 17 · also BCM, CD269, TNFRSF13A, BCMA · CD molecules

22 programs in company-led studies act on TNFRSF17, from 17 companies: 9 in phase 3, 3 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (14 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
linvoseltamabruleRegeneron Pharmaceuticals–phase 41312 runningCD3ENCIt
teclistamabruleJohnson & Johnson–phase 41110 runningCD3ENCIt
elranatamabrulePfizer–phase 4159 runningCD3ENCIt
belantamab mafodotinruleGlaxoSmithKline–phase 32518 running–NCIt
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZeneca–phase 31212 runningCD19a judged reading
etentamigAbbVie–phase 31111 runningCD3Ethe company's pipeline
ramantamigJohnson & Johnson–phase 388 runningCD3E, GPRC5Da judged reading
anitocabtagene autoleucelruleGilead Sciences–phase 366 running–NCIt
equecabtagene autoleucelruleNanjing IASO Biotechnology–phase 354 running–NCIt
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceutical–phase 344 runningCD3Ethe company's pipeline
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologics–phase 344 runningCD3E, GPRC5DNCIt
Evarucabgene AutoleucelruleNexcella–phase 322 running–NCIt
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesruleCartesian Therapeutics–phase 264 running–NCIt
cizutamigruleUCB–phase 252 runningCD3ENCIt
belantamabGlaxoSmithKline–phase 232 running–the company's pipeline
vonsetamigruleRegeneron Pharmaceuticals–phase 232 runningCD3ENCIt
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbVie–phase 222 runningCD38, CD3Ethe company's pipeline
pamlectabart tismanitinruleHeidelberg Pharma–phase 222 running–NCIt
Allogeneic Anti-BCMA CAR T-cells AZD4045AstraZeneca–phase 211 running–a judged reading
BCMA-CD19 Compound CAR T CellsruleiCell Gene Therapeutics–phase 133 runningCD19NCIt
LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010ruleKelonia Therapeutics–phase 111 runningCD3ENCIt
tunlucabtagene autoleucelBristol-Myers Squibb–phase 111 runningGPRC5Da judged reading

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.